BioMed Research International

Research Article

Preliminary Evaluation of the Diagnostic Usefulness of Uroplakin 2 with an Assessment of the Antioxidant Potential of Patients with Bladder Cancer

Table 2

(a) UP2 level in the plasma in BC patients and control group


Groups	UP2			p-value
	in plasma [ng/mL]
	Me	Mean	SD	in plasma

BC	3.65	3.71	1.29	p≤0.001 BC vs C
C	2.63	2.72	0.68

NMIBC	3.55	3.73	1.40	p=0.650 NMIBC vsMIBC
				p≤0.001 NMIBC vs C
MIBC	3.45	3.64	0.90
				p=0.003 MIBC vs C

LG	3.43	3.60	1.20	p=0.789 LG vs HG
				p≤0.001 LG vs C
HG	3.47	3.83	1.39
				p≤0.001 HG vs C

M	3.65	3.87	1.34	p≤0.001 M vs W
W	2.97	2.89	0.48

Non-smoking BC	3.46	3.93	1.98	p=0.659 non-smoking BC vs smoking BC
Smoking BC	3.25	3.66	1.11

UP2: uroplakin 2; BC: patients group; C: control group; NMIBC: non-muscle invasive BC; MIBC: muscle invasive BC; LG: low grade; HG: high grade; M: men; W: women; SD: standard deviation; p: statistically significant difference; Me: median.

(b) UP2 level in the urine in BC patients and control group


Groups	UP2			p-value
	in urine [ng/mg cr.]
	Me	Mean	SD	in urine

BC	0.24	0.50	0.58	p≤0.001 BC vs C
C	0.07	0.08	0.04

NMIBC	0.26	0.54	0.64	p=0.939 NMIBC vs MIBC
				p≤0.001 NMIBC vs C
MIBC	0.24	0.38	0.32
				MIBC vs C p≤0.001

LG	0.25	0.55	0.66	p=0.846 LG vs HG
				p≤0.001 LG vs C
HG	0.26	0.45	0.47
				p≤0.001 HG vs C

M	0.24	0.50	0.62	p=0.386 M vs W
W	0.56	0.49	0.31

Non-smoking BC	0.64	0.85	0.90	p=0.640 non-smoking BC vs smoking BC
Smoking BC	0,24	0.43	0.46